Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.

Abrocitinib may effectively treat stubborn alopecia universalis.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib may help treat nail dystrophy, especially when other treatments fail.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.